Home / Stock ratings / EDIT
Stock rating · Biological Products, (No Diagnostic Substances)
Editas Medicine, Inc. (EDIT) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Editas Medicine, Inc. 64 out of 100 (Promising). Its highest factor score is earnings track record at 100, and its lowest is business quality at 24.
MELANY ratingRated 2026-10-06EDIT · composite score
About Editas Medicine, Inc.
Editas Medicine Inc is a clinical-stage genome editing company developing genomic medicines for a broad range of serious diseases. Its proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex with an enzyme such as Cas9 (CRISPR-associated protein 9) or Cas12a (also known as Cpf1).
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why EDIT scores 64/100
EDIT's 8 factor scores run from 24 to 100, and 4 of them sit above its composite of 64. Here is how EDIT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +33%
What Wall Street price targets and revisions are signalling.
- Analyst targets 110% upside
- Institutional net buying +44.9%
Near-term events that could move the stock.
- Earnings in 34 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How EDIT compares
As of October 7, 2026, Editas Medicine, Inc. is tied for 7th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 65.
Key risks for EDIT
- Operating margin -164%, cash-burn business, dependent on capital markets
- Negative free cash flow, company consuming cash, not generating it
- Short interest 20% of float, high volatility risk on news
- High beta 2.0, amplifies market drawdowns 1.8x+ in selloffs
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Editas Medicine, Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds EDIT's momentum and catalyst factors above.
EDIT trade plan (Pro)
MELANY has a full position plan for Editas Medicine, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates EDIT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Editas Medicine, Inc.'s 64/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about EDIT
Is Editas Medicine, Inc. (EDIT) a buy?
As of 2026-10-06, MELANY rated Editas Medicine, Inc. Promising with a composite score of 64/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Editas Medicine, Inc.'s MELANY score?
Editas Medicine, Inc. (EDIT) has a MELANY composite score of 64/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the EDIT stock rating calculated?
MELANY scores EDIT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Editas Medicine, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Editas Medicine, Inc. (EDIT) Promising with a composite of 64/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the EDIT stock price forecast?
MELANY does not publish price targets or forecasts for EDIT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 64/100 across eight factors for Editas Medicine, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is EDIT stock overvalued or undervalued?
MELANY's valuation factor currently reads 59/100 for Editas Medicine, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives EDIT's read.
What price should I buy EDIT at?
Rather than chasing the current price, MELANY computes a smart entry zone for EDIT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying EDIT stock?
The top risks MELANY currently flags for Editas Medicine, Inc.: Operating margin -164%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 20% of float, high volatility risk on news; High beta 2.0, amplifies market drawdowns 1.8x+ in selloffs; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Editas Medicine, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 24/100 for Editas Medicine, Inc., and earnings track record, at 100/100. The 64/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will EDIT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 71/100 for EDIT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this EDIT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores EDIT continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, EDIT included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.